Lung Cancer News Update

Key Genetic Code Change Drives Common Lung Cancer Type “A team led by researchers at NYU Langone Health’s Perlmutter Cancer Center has identified a gene that drives development of the second most common type of lung carcinoma, offering greater insight into how the disease might someday be treated.” Nine Takeaways from Recent Meta-Analysis on Lung Cancer Screening with Low-Dose CT “From incidental findings and screening for chronic obstructive pulmonary disease (COPD) to surveillance imaging protocols and the advent of artificial intelligence (AI), the authors of a new meta-analysis examine insights and emerging trends from the last two decades of research on the use of low-dose computed tomography (CT) in lung cancer screening.” Novel lung cancer biomarker “They found that circulating p53 autoantibodies were associated with the subsequent development of lung cancer in African Americans, but not European Americans, and in lung cancer cases diagnosed within four years of blood collection.” Fighting lung cancer with technology “Dr. Nadeem explains how the minimally invasive robotic surgery works: “We use it to isolate patients’ nodules, sample those nodules to get results on whether they are cancerous and then complete the procedure if they are,” he says. “Compared to the traditional method, the risk of complications with the robot is very low. The length of stay is also shorter, and there are fewer transfusions and less blood loss.”” Concurrent Antibiotics, Steroids Raise CDI Risk in People With Lung Cancer Receiving EGFR-TKIs “The new report found no evidence that second-generation tyrosine kinase inhibitors (TKIs) were more likely to lead to Clostridioides difficile infection (CDI) in patients with lung cancer.” Novel Cell ‘Switches’ Promote Lung Cancer Growth, Treatment Resistance “Northwestern Medicine investigators have revealed new insights into how cancer cells can change their form by undergoing phenotypic “switches” to facilitate tumor growth and treatment resistance in small cell lung cancer, according to findings published in Science Advances.“ Scientists Detail Major Mechanism Lung Cancers Use to Evade Immune Attack “A protein commonly found at high levels in lung cancer cells controls a major immunosuppressive pathway that allows lung tumors to evade immune attack, according to a study led by researchers at Weill Cornell Medicine. The discovery could hasten the development of treatments that overcome this tumor defense mechanism and improve outcomes for lung cancer patients.” Can Dual-Energy CT Have an Impact in Differentiating Primary Lung Cancer and Pulmonary Metastases? “In comparison to primary lung cancer, pulmonary metastases had a 33 percent higher frequency of ring-like peripheral high iodine concentration on dual-energy computed tomography (DECT), according to a new retrospective study.” FDA Grants Breakthrough Device Designation to OncobiotaLUNG Assay for Lung Cancer Detection “The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma. The OncobiotaLUNG assay is microbiome-driven liquid biopsy platform used for the early detection of lung cancer. The device categorizes lung nodule samples into those that are considered high or low-risk for malignancy based off of a blood draw from the patient. According to the new designation, the company is expecting prioritized reviews from the agency regarding upcoming trials further analyzing the effectiveness of the assay.” FDA Grants Orphan Drug Designation to JBI-802 for Small Cell Lung Cancer and Acute Myeloid Leukemia “The FDA gave the dual epigenetic modulator JBI-802 an orphan drug designation to treat small cell lung cancer and acute myeloid leukemia.” Video: Dr. Hirsch on Diagnosing and Managing Metastatic SCLC “Fred R. Hirsch, MD, PhD, discusses the rarity of diagnosing small cell lung cancer early in the disease course, unmet needs in SCLC screening, the importance of ECOG performance score when considering patients for clinical trials, and factors influencing hospice care decisions in patients with SCLC.”